Skip to Content

Grifols SA GIFLF Stock Quote

| Rating as of

PINX:GIFLF

Morningstar‘s Stock Analysis GIFLF

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics GIFLF

Company Profile GIFLF

Business Description

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue (following the Biotest acquisition).

Contact
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan
Barcelona, 08174, Spain
T +34 935710500
Industry Drug Manufacturers - General
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2022
Employees 27,000